Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 2/20 | 0.35 |
| ▸ | ACHE | P22303 | 2/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8268207 | 0.90 | ACHE (0.37) | LTA4HBCHEACHEFAAH | |
| SCHEMBL8269180 | 0.89 | KDM4E (0.41) | BCHEACHE | |
| SCHEMBL13513892 | 0.84 | CHRM4 (0.36) | LTA4H | |
| SCHEMBL8267595 | 0.84 | SCN1A (0.37) | — | |
| SCHEMBL8269169 | 0.84 | GPBAR1 (0.36) | FAAH | |
| SCHEMBL13513834 | 0.83 | HTR1A (0.33) | NR1H2DRD2DRD4LTA4H | |
| SCHEMBL8268946 | 0.82 | PSEN1 (0.40) | LTA4H | |
| SCHEMBL13611497 | 0.82 | TEAD1 (0.43) | — | |
| SCHEMBL8269820 | 0.82 | FFAR4 (0.38) | FAAH | |
| SCHEMBL13513826 | 0.82 | MAPT (0.38) | DRD2DRD4ACHEFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7638629-B2 | Piperidines and related compounds for treatment of alzheimer's disease | Merck Sharp & Dohme Ltd, (GB) | 2009-12-29 | — | — | US | disclosed |
| US-20080021043-A1 | Piperidines and Related Compounds for Treatment of Alzheimer's Disease | MERCK SHARP & DOHME LTD. (GB) | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021043-A1 | Piperidines and Related Compounds for Treatment of Alzheimer's Disease | PSEN1, PSEN2, APP | NR1H2 464/4885DRD2 953/4885DRD4 1655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.